UAE
Bahrain
Jordan
Kuwait
Oman
Qatar
Saudi ArabiaHealth News
Salmonella biofilms incredibly resistant to powerful disinfectants
Date: Jan-19-2014Once Salmonella bacteria get into a food processing facility and have an opportunity to form a biofilm on surfaces, it is likely to be extraordinarily difficult, if not impossible, to kill it, according to research published ahead of print in the journal Applied and Environmental Microbiology.Researchers from National University of Ireland, Galway conducted a study in which they attempted to kill Salmonella biofilms on a variety of hard surfaces, using three types of disinfectant.
Articles in Health Affairs examine the toll of diabetes, both in the US and abroad
Date: Jan-19-2014Poorer Americans: depleted food budgets can mean higher risk of hypoglycemia.For generations, economists have noted that low-income households spend much of their earnings as soon as their paychecks arrive. Since a large proportion of Americans are paid at the beginning of the month, many low-income households exhaust food budgets by month's end.Hilary K. Seligman of the University of California, San Francisco, and coauthors, postulated that this could influence health outcomes, such as heightened risk for low blood sugar (hypoglycemia) among people with diabetes.
Promising results of phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer
Date: Jan-19-2014An article published in the January issue of the International Journal of Radiation Oncology, Biology and Physics reports results of the Radiation Therapy Oncology Group (RTOG) phase II clinical trial of Bevacizumab (Avastin) in addition to cisplatin and pelvic radiation for locally advanced cervical cancer. The group reports that the addition of Bevacizumab to the existing standard of care was safe and showed promising overall results. The 2- and 3- year overall survival rates were 89.8 percent and 80.2 percent, respectively.
Most practice guideline recommendations based on less-than-ideal quality of evidence
Date: Jan-19-2014A study published in the January issue of Mayo Clinic Proceedings shows that most clinical practice guidelines for interventional procedures (e.g., bronchoscopy, angioplasty) are based on lower-quality medical evidence and fail to disclose authors' conflicts of interest."Guidelines are meant to create a succinct roadmap for the diagnosis and treatment of medical conditions by analyzing and summarizing the increasingly abundant medical research," write Joseph Feuerstein, M.D., and colleagues from Beth Israel Deaconess Medical Center.
Promising results of phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer
Date: Jan-19-2014An article published in the January issue of the International Journal of Radiation Oncology, Biology and Physics reports results of the Radiation Therapy Oncology Group (RTOG) phase II clinical trial of Bevacizumab (Avastin) in addition to cisplatin and pelvic radiation for locally advanced cervical cancer. The group reports that the addition of Bevacizumab to the existing standard of care was safe and showed promising overall results. The 2- and 3- year overall survival rates were 89.8 percent and 80.2 percent, respectively.
Application of global sequencing technology reveals how an activator of gene expression stays focused
Date: Jan-19-2014At a glance, DNA is a rather simple sequence of A, G, C, T bases, but once it is packaged by histone proteins into an amalgam called chromatin, a more complex picture emerges. Histones, which come in four subtypes - H2A, H2B, H3, and H4 - can either coil DNA into inaccessible silent regions or untwist it to allow gene expression. To further complicate things, small chemical flags, such as methyl groups, affect whether histones silence or activate genes.Among activator histones is a form of H3 decorated at a precise location (defined as H3K4) with three methyl groups (known as "H3K4me3").
Coevolution between humans and bacteria found to reduce gastric cancer risk
Date: Jan-19-2014Research carried out in two distinct communities in Colombia illustrates how coevolution between humans and bacteria can affect a person's risk of disease. Working with colleagues in Columbia and the U.S., Scott Williams, PhD, a professor of genetics at the Geisel School of Medicine and the Institute of Quantitative Biomedical Sciences (iQBS) at Dartmouth, and his graduate student Nuri Kodaman discovered that the risk of developing gastric cancer depends heavily on both the ancestry of the person and the ancestry of Helicobacter pylori with which that person is infected.
Application of global sequencing technology reveals how an activator of gene expression stays focused
Date: Jan-19-2014At a glance, DNA is a rather simple sequence of A, G, C, T bases, but once it is packaged by histone proteins into an amalgam called chromatin, a more complex picture emerges. Histones, which come in four subtypes - H2A, H2B, H3, and H4 - can either coil DNA into inaccessible silent regions or untwist it to allow gene expression. To further complicate things, small chemical flags, such as methyl groups, affect whether histones silence or activate genes.Among activator histones is a form of H3 decorated at a precise location (defined as H3K4) with three methyl groups (known as "H3K4me3").
Coevolution between humans and bacteria found to reduce gastric cancer risk
Date: Jan-19-2014Research carried out in two distinct communities in Colombia illustrates how coevolution between humans and bacteria can affect a person's risk of disease. Working with colleagues in Columbia and the U.S., Scott Williams, PhD, a professor of genetics at the Geisel School of Medicine and the Institute of Quantitative Biomedical Sciences (iQBS) at Dartmouth, and his graduate student Nuri Kodaman discovered that the risk of developing gastric cancer depends heavily on both the ancestry of the person and the ancestry of Helicobacter pylori with which that person is infected.
Fewer years of life lost to cancer
Date: Jan-19-2014Since the enactment of the National Cancer Act in 1971, the U.S. has spent hundreds of billions of dollars in cancer research and treatment. And yet, the cancer mortality rate - the historic benchmark of progress - has only declined modestly while the mortality rates of other leading causes of death have declined substantially. This difference has led many to question whether we've made progress in the 'War on Cancer'. The answer is definitively yes according to Norris Cotton Cancer Center research published in the Journal of Clinical Oncology.
Stay Connected
